5 Key Takeaways

• 1

  Advances in human genetics, circuit biology, and translational biomarkers have expanded researchers’ ability to investigate the biology underlying psychiatric disorders.

• 2

  Earlier target-engagement assessments and closer collaboration between discovery and clinical teams help evaluate mechanisms before programs advance.

• 3

  EEG and brain imaging approaches, including receptor occupancy imaging and fMRI, are used or explored to assess target engagement and support dose selection.

• 4

  Computational and multimodal methods may help researchers analyze heterogeneous data and identify psychiatric disease subgroups.

• 5

  Fluid biomarkers, including inflammatory markers associated with an immunometabolic profile in some patients with depression, may help define subpopulations for study.